Abstract Number: 2120 • ACR Convergence 2023
Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections
Background/Purpose: How interstitial lung disease (ILD) and airway disease (AD) independently affect the clinical course of rheumatoid arthritis (RA) is unclear since previous studies conflated…Abstract Number: 2136 • ACR Convergence 2023
Arthritogenic Cells Found in the Peripheral Blood of Rheumatoid Arthritis Patients Transfer the Disease to NSG-DR4 Mice
Background/Purpose: T cells play an important role in the genesis of rheumatoid arthritis (RA). HLA class II genes, such as HLA-DRB1*0401 (HLA-DR4), confer the strongest…Abstract Number: 2152 • ACR Convergence 2023
Survival Benefits of Knee and Hip Arthroplasty in Patients with Rheumatoid Arthritis: A General Population-based Cohort Study
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular disease (CVD), venous thromboembolism (VTE), and mortality. Many patients with RA underwent knee and…Abstract Number: 2169 • ACR Convergence 2023
Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…Abstract Number: 2438 • ACR Convergence 2023
Synovial Tissue Single-Cell Analysis Demonstrates Differential Fibroblast Populations Between RA and PsA Which Display Distinct Function
Background/Purpose: Synovial fibroblasts (FLS) are key contributors to joint inflammation and damage in patients with Rheumatoid (RA) and Psoriatic Arthritis (PsA). Recent studies have identified…Abstract Number: 2539 • ACR Convergence 2023
Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA
Background/Purpose: A key target of RA treatment is to achieve early and sustained remission in order to ensure lower levels of long-term structural joint damage…Abstract Number: PP10 • ACR Convergence 2023
Saved by Plants: How a Necessary Lifestyle Change Led to a Happier Life with Decreased Rheumatoid Arthritis Pain and Fatigue
Background/Purpose: After my RA diagnosis over eleven years ago, I was optimistic that the first biologic DMARD I took would slow the progression of my…Abstract Number: 0024 • ACR Convergence 2023
Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay
Background/Purpose: In rheumatoid arthritis [RA], synovial biopsies were shown to guide therapy selection1. However, biopsies require special training for clinicians and are semi-invasive for patients.…Abstract Number: 0086 • ACR Convergence 2023
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Background/Purpose: Checkpoint antagonist therapeutics have transformed the field of oncology while advancing the understanding of adequate checkpoint activity in preventing autoimmunity. Checkpoint agonism represents a…Abstract Number: 0220 • ACR Convergence 2023
Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death
Background/Purpose: The benefits of antiviral therapy in the COVID-19 patients with underlying rheumatic disease with or without immunosuppression are not entirely clear. The goal of…Abstract Number: 0385 • ACR Convergence 2023
Heterogeneity of the Joint Location Supports the Importance of Local Factors in Early RA Synovitis : Analysis of the ERA UCLouvain Brussels Cohort
Background/Purpose: ERA is considered to be a systemic disorder, but the role of local factors in driving synovial inflammation is increasingly being recognized. These joint-specific…Abstract Number: 0401 • ACR Convergence 2023
Resolution of Swollen Joint Count Is an Important Clinical Objective in Early Rheumatoid Arthritis : Analysis of the UCLouvain Brussels ERA Cohort and Comparison with the Remission Composite Index
Background/Purpose: Rheumatoid Arthritis is a chronic autoimmune disease characterized by persistent joint inflammation. According to international guidelines, the treatment target should aim to reach the…Abstract Number: 0418 • ACR Convergence 2023
Synovial Fluid Cell Counts Associated with Joint Histopathology in Rheumatoid Arthritis
Background/Purpose: While analysis of synovial fluid white blood cell counts (WBCs) is performed in clinical practice for diagnosing septic arthritis and differentiating noninflammatory from inflammatory…Abstract Number: 0435 • ACR Convergence 2023
Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following Release of Safety Data
Background/Purpose: The ORAL Surveillance study highlighted risks of cardiac events, thromboembolism (VTE), and cancer associated with Janus kinase inhibitors (JAKi). The aim of this study…Abstract Number: 0452 • ACR Convergence 2023
Real Life Safety and Survival of Targeted Therapies in Arthritis Patients over Age of 65
Background/Purpose: Prognosis for chronic inflammatory arthritis is drastically improved over previous decades and older patients are treated with targeted therapies (TTs) (biological or synthetic targeted…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 155
- Next Page »